Genetic variation associated with ischemic heart failure: A HuGE review and meta-analysis

American Journal of Epidemiology

Volumn 166, Issue 6, 2007, Pages 619-633

  Kitsios, Georgios ^a   Zintzaras, Elias ^a,b,c  

^a UNIVERSITY OF THESSALY   (Greece)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c TUFTS MEDICAL CENTER   (United States)

Author keywords

Epidemiology; Heart failure, congestive; Meta analysis; Myocardial ischemia; Polymorphism, genetic; Variation (genetics)

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR; ANGIOTENSINOGEN; ARGININE; ASPARAGINE; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; DIPEPTIDYL CARBOXYPEPTIDASE; ENDOTHELIN 1; GLUTAMIC ACID; GLUTAMINE; GLYCINE; LYSINE; NEUROHORMONE; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

CARDIOVASCULAR DISEASE; EPIDEMIOLOGY; ETIOLOGY; GENETIC VARIATION; META-ANALYSIS; POLYMORPHISM;

CASE CONTROL STUDY; CONFIDENCE INTERVAL; EPIDEMIOLOGICAL DATA; GENE DELETION; GENE INSERTION; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HEART FAILURE; HORMONAL REGULATION; HUMAN; HUMAN GENOME; ISCHEMIC HEART DISEASE; PATHOGENICITY; RECESSIVE INHERITANCE; REVIEW; SYSTEMATIC REVIEW;

CASE-CONTROL STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HEART FAILURE, CONGESTIVE; HUMANS; MYOCARDIAL ISCHEMIA; POLYMORPHISM, GENETIC; PROGNOSIS; RISK FACTORS; VARIATION (GENETICS);

EID: 34548308987     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwm129     Document Type: Review

References (130)

1. Givertz MM, Colucci WS, Braunwald E. Clinical aspects of heart failure; pulmonary edema, high-output failure. In: Zipes DP, Libby P, Bonow RO, et al, eds. Braunwald's heart disease: a textbook of cardiovascular medicine. 7th ed. Philadelphia, PA: Elsevier Saunders, 2005:539-68.
2. Ho KK, Pinsky JL, Kannel WB, et al. The epidemiology of heart failure: The Framingham Study. J Am Coll Cardiol 1993;22:6A-13A.
3. Packer M, Coats AJS, Fowler MB, et al. Effect of carvedilol on the survival of patients with severe chronic heart failure. N Engl J Med 2001;344:1651-8.
4. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 1987;316:1429-35.
5. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001-7.
6. Bart BA, Shaw LK, McCants CB, et al. Clinical determinants of mortality in patients with angiographically diagnosed ischemic or nonischemic cardiomyopathy. J Am Coll Cardiol 1997;30:1002-8.
7. Adams KF, Dunlap SH, Sueta CA, et al. Relation between gender, etiology and survival in patients with symptomatic heart failure. J Am Coll Cardiol 1996;28:1781-8.
8. Felker GM, Shaw LK, O'Connor CM. A standardized definition of ischemic cardiomyopathy for use in clinical research. J Am Coll Cardiol 2002;39:210-18.
9. Chiodini BD, Lewis CM. Meta-analysis of 4 coronary heart disease genome-wide linkage studies confirms a susceptibility locus on chromosome 3q. Arterioscler Thromb Vasc Biol 2003;23:1863-8.
10. Zintzaras E, Kitsios G. Identification of chromosomal regions linked to premature myocardial infarction: a meta-analysis of whole-genome searches. J Hum Genet 2006;51:1015-21.
11. Wang Q. Molecular genetics of coronary artery disease. Curr Opin Cardiol 2005;20:182-8.
12. Bleumink GS, Schut AF, Sturkenboom MC, et al. Genetic polymorphisms and heart failure. Genet Med 2004;6:465-74.
13. Galasko GI, Senior R, Lahiri A. Ethnic differences in the prevalence and aetiology of left ventricular systolic dysfunction in the community: the Harrow heart failure watch. Heart 2005;91:595-600.
14. Liggett SB, Mialet-Perez J, Thaneemit-Chen S, et al. A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc Natl Acad Sci U S A 2006;103:11288-93.
15. Richards M, Nichols G, Espiner E, et al. B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction. Circulation 2003;107:2786-92.
16. Horne BD, Camp NJ, Muhlestein JB, et al. Identification of excess clustering of coronary heart diseases among extended pedigrees in a genealogical population database. Am Heart J 2006;152:305-11.
17. Bridgman P, Aronovitz MA, Kakkar R, et al. Gender-specific patterns of left ventricular and myocyte remodeling following myocardial infarction in mice deficient in the angiotensin II type 1a receptor. Am J Physiol Heart Circ Physiol 2005;289:H586-92.
18. Krishnamurthy P, Subramanian V, Singh M, et al. Deficiency of beta1 integrins results in increased myocardial dysfunction after myocardial infarction. Heart 2006;92:1309-15.
19. Zintzaras E, Ioannidis JP. Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol 2005;28:123-37.
20. Zintzaras E, Rodopoulou P, Koukoulis GN. BsmI, TaqI, ApaI and FokI polymorphisms in the vitamin D receptor (VDR) gene and the risk of osteoporosis: a meta-analysis. Dis Markers 2006;22:317-26.
21. Zintzaras E. Association of methylenetetrahydrofolate reductase (MTHFR) polymorphisms with genetic susceptibility to gastric cancer: a meta-analysis. J Hum Genet 2006;51:618-24.
22. Whitehead A. Meta-analysis of controlled clinical trials. Chichester, United Kingdom: Wiley, 2002.
23. Ioannidis JP, Trikalinos TA, Zintzaras E. Extreme between-study homogeneity in meta-analyses could offer useful insights. J Clin Epidemiol 2006;59:1023-32.
24. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
25. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88.
26. Zintzaras E, Kitsios G, Stefanidis I. Endothelial NO synthase gene polymorphisms and hypertension: a meta-analysis. Hypertension 2006;48:700-10.
27. Zintzaras E, Stefanidis I, Santos M, et al. Do alcohol-metabolizing enzyme gene polymorphisms increase the risk of alcoholism and alcoholic liver disease? Hepatology 2006;43:352-61.
28. Zintzaras E, Koufakis T, Ziakas PD, et al. A meta-analysis of genotypes and haplotypes of methylenetetrahydrofolate reductase gene polymorphisms in acute lymphoblastic leukemia. Eur J Epidemiol 2006;21:501-10.
29. Zintzaras E, Stefanidis I. Association between the GLUT1 gene polymorphism and the risk of diabetic nephropathy: a meta-analysis. J Hum Genet 2005;50:84-91.
30. Zintzaras E, Hadjigeorgiou GM. Association of paraoxonase 1 gene polymorphisms with risk of Parkinson's disease: a metaanalysis. J Hum Genet 2004;49:474-81.
31. Raynolds MV, Bristow MR, Bush EW, et al. Angiotensin-converting enzyme DD genotype in patients with ischaemic or idiopathic dilated cardiomyopathy. Lancet 1993;342:1073-5.
32. Sanderson JE, Young RP, Yu CM, et al. Lack of association between insertion/deletion polymorphism of the angiotensin-converting enzyme gene and end-stage heart failure due to ischemic or idiopathic dilated cardiomyopathy in the Chinese. Am J Cardiol 1996;77:1008-10.
33. Akbulut T, Bilsel T, Terzi S, et al. Relationship between ACE gene polymorphism and ischemic chronic heart failure in Turkish population. Eur J Med Res 2003;8:247-53.
34. Covolo L, Gelatti U, Metra M, et al. Angiotensin-converting-enzyme gene polymorphism and heart failure: a case-control study. Biomarkers 2003;8:429-3.
35. Huang W, Xie C, Zhou H, et al. Association of the angiotensin-converting enzyme gene polymorphism with chronic heart failure in Chinese Han patients. Eur J Heart Fail 2004;6:23-7.
36. Goldbergova M, Spinarova L, Spinar J, et al. Association of two angiotensinogen gene polymorphisms, M235T and G(-6)A, with chronic heart failure. Int J Cardiol 2003;89:267-72.
37. Small KM, Wagoner LE, Levin AM, et al. Synergistic polymorphisms of β1- and α2c-adrenergic receptors and the risk of congestive heart failure. N Engl J Med 2002;347:1135-42.
38. Metra M, Zani C, Covolo L, et al. Role of β1- and a2c-adrenergic receptor polymorphisms and their combination in heart failure: a case-control study. Eur J Heart Fail 2006;8:131-5.
39. Covolo L, Gelatti U, Metra M, et al. Role of beta1- and beta2-adrenoceptor polymorphisms in heart failure: a case-control study. Eur Heart J 2004;25:1534-41.
40. Leineweber K, Tenderich G, Wolf C, et al. Is there a role of the Thr164Ile-beta(2)-adrenoceptor polymorphism for the outcome of chronic heart failure? Basic Res Cardiol 2006;101:479-84.
41. Colombo MG, Ciofini E, Paradossi U, et al. ET-1 Lys198Asn and ET(A) receptor H323H polymorphisms in heart failure. A case-control study. Cardiology 2006;105:246-52.
42. Alikasifoglu M, Tokgozoglu L, Acil T, et al. Tumor necrosis factor-alpha polymorphism in Turkish patients with dilated cardiomyopathy. Eur J Heart Fail 2003;5:161-3.
43. Densem CG, Hutchinson IV, Yonan N, et al. Tumour necrosis factor alpha gene polymorphism: a predisposing factor to non-ischaemic myocardial dysfunction? Heart 2002;87:153-5.
44. Kubota T, McNamara DM, McTiernan CF, et al. Effects of tumour necrosis factor gene polymorphisms on patients with congestive heart failure. Circulation 1998;97:2499-501.
45. Holweg CT, Baan CC, Niesters HG, et al. TGF-beta1 gene polymorphisms in patients with end-stage heart failure. J Heart Lung Transplant 2001;20:979-84.
46. van der Meer P, De Boer RA, White HL, et al. The VEGF +405 CC promoter polymorphism is associated with an impaired prognosis in patients with chronic heart failure: a MERIT-HF substudy. J Card Fail 2005;11:279-84.
47. Holweg CT, Balk AH, Uitterlinden AG, et al. Functional heme oxygenase-1 promoter polymorphism in relation to heart failure and cardiac transplantation. J Heart Lung Transplant 2005;24:493-7.
48. Bijlsma FJ, Bruggink AH, Hartman M, et al. No association between IL-10 promoter gene polymorphism and heart failure or rejection following cardiac transplantation. Tissue Antigens 2001;57:151-3.
49. Bijlsma FJ, vanKuik J, Tilanus MG, et al. Donor interleukin-4 promoter gene polymorphism influences allograft rejection after heart transplantation. J Heart Lung Transplant 2002;21:340-6.
50. Kolek MJ, Carlquist JF, Thaneemit-Chen S, et al. The role of a common adenosine monophosphate deaminase (AMPD)-1 polymorphism in outcomes of ischemic and nonischemic heart failure. J Card Fail 2005;11:677-83.
51. Kruger S, Graf J, Merx MW, et al. CD14 gene -260 C/T polymorphism is associated with chronic heart failure. Eur J Intern Med 2005;16:345-7.
52. Nakatani D, Sato H, Sakata Y, et al. Influence of serotonin transporter gene polymorphism on depressive symptoms and new cardiac events after acute myocardial infarction. Am Heart J 2005;150:652-8.
53. Glazier AM, Nadeau JH, Aitman TJ. Finding genes that underlie complex traits. Science 2002;298:2345-9.
54. Delgado RM, Willerson J. Pathophysiology of heart failure. A look at the future. Tex Heart Inst J 1999;26:28-33.
55. Melo LG, Pachori AS, Kong D, et al. Gene and cell-based therapies for heart disease. FASEB J 2004;18:648-63.
56. Risch NJ. Searching for genetic determinants in the new millennium. Nature 2000;405:847-56.
57. Sherry ST, Ward MH, Kholodov M, et al. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res 2001;29:308-11.
58. Sigurdsson A, Swedberg K. Neurohormonal activation and congestive heart failure: today's experience with ACE inhibitors and rationale for their use. Eur Heart J 1995;16:S65-72.
59. Rigat B, Hubert C, Alhenc-Gelas F, et al. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990;86:1343-6.
60. Tiret L, Rigat B, Visvikis S, et al. Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels. Am J Hum Genet 1992;51:197-205.
61. Staessen JA, Wang JG, Ginocchio G, et al. The deletion/insertion polymorphism of the angiotensin converting enzyme gene and cardiovascular-renal risk. J Hypertens 1997;15:1579-92.
62. Lee EJD. Population genetics of the angiotensin-converting enzyme in Chinese. Br J Clin Pharmacol 1994;37:212-14.
63. Sethi AA, Nordestgaard BG, Hansen AT. Angiotensinogen gene polymorphism, plasma angiotensinogen, and risk of hypertension and ischemic heart disease. A meta-analysis. Arterioscler Thromb Vasc Biol 2003;23:1269-75.
64. Tamura K, Umemura S, Ishii M, et al. Molecular mechanism of transcriptional activation of angiotensinogen gene by proximal promoter. J Clin Invest 1994;93:1370-9.
65. Yanai K, Nibu Y, Murakami K, et al. A cis-acting DNA element located between TATA box and transcription initiation site is critical in response to regulatory sequences in human angiotensinogen gene. J Biol Chem 1996;271:15981-6.
66. Brodde OE, Bruck H, Leineweber K. Cardiac adrenoceptors: physiological and pathophysiological relevance. J Pharmacol Sci 2006;100:323-37.
67. Bristow M. Antiadrenergic therapy of chronic heart failure: surprises and new opportunities. Circulation 2003;107:1100-2.
68. Small KM, Forbes SL, Rahman FF, et al. A four amino acid deletion polymorphism in the third intracellular loop of the human alpha 2C-adrenergic receptor confers impaired coupling to multiple effectors. J Biol Chem 2000;275:23059-64.
69. Maqbool A, Hall AS, Ball SG, et al. Common polymorphisms of b1-adrenoceptor: identification and rapid screening assay. Lancet 1999;353:897.
70. Halushka MK, Fan JB, Bentley K, et al. Pattern of single-nucleotide polymorphisms in candidate genes for blood-pressure homeostasis. Nat Genet 1999;22:239-47.
71. Liggett SB. Polymorphisms of the b2-adrenergic receptor and asthma. Am J Respir Crit Care Med 1997;156:S156-62.
72. Green SA, Turki J, Innis M, et al. Amino-terminal polymorphisms of the human b2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry 1994;33:9414-19.
73. Dishy V, Sofowora G, Xie H, et al. The effect of common polymorphisms of the b2-adrenergic receptor on agonist-mediated vascular desensitisation. N Engl J Med 2001;345:1030-5.
74. Xie H, Stein C, Kim R, et al. Frequency of functionally important b-2 adrenoceptor polymorphisms varies markedly among African-American, Caucasian and Chinese individuals. Pharmacogenetics 1999;9:511-16.
75. Green SA, Cole G, Jacinto M, et al. A polymorphism of the human b2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor. J Biol Chem 1993;268:23116-21.
76. Sutsch G, Kiowski W. Endothelin and endothelin receptor antagonism in heart failure. J Cardiovasc Pharmacol 2000;35:S69-73.
77. Barden AE, Herbison CE, Beilin LJ, et al. Association between the endothelin-1 gene Lys198Asn polymorphism, blood pressure, and plasma endothelin-1 levels in normal and pre-eclamptic pregnancy. J Hypertens 2001;19:1775-82.
78. Tanaka C, Kamide K, Takiuchi S, et al. Evaluation of the Lys198Asn and 134delA genetic polymorphisms of the endothelin 1 gene. Hypertens Res 2004;27:367-71.
79. Herrmann SM, Schmidt-Petersen K, Pfeifer J, et al. A polymorphism in the endothelin-A receptor gene predicts survival in patients with idiopathic dilated cardiomyopathy. Eur Heart J 2001;22:1948-53.
80. Morita T, Mitsialis SA, Koike H, et al. Carbon monoxide controls the proliferation of hypoxic vascular smooth muscle cells. J Biol Chem 1997;272:32804-9.
81. Willis D, Moore AR, Frederick R, et al. Heme oxygenase: a novel target for the modulation of the inflammatory response. Nat Med 1996;2:87-90.
82. Chen YH, Lin SJ, Lin MW, et al. Microsatellite polymorphism in promoter of heme oxygenase-1 gene is associated with susceptibility to coronary artery disease in type 2 diabetic patients. Hum Genet 2002;111:1-8.
83. Tsurumi Y, Krasinski K, Chen D, et al. Reciprocal relationship between VEGF and NO in the regulation of endothelial integrity. Nat Med 1997;3:879-86.
84. De Boer RA, Pinto YM, van Veldhuisen DJ. The imbalance between oxygen demand and supply as a potential mechanism in the pathophysiology of heart failure: the role of microvascular growth and abnormalities. Microcirculation 2003;10:113-26.
85. Watson CJ, Webb NJA, Bottomley MJ, et al. Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine 2000;12:1232-5.
86. Stevens A, Soden J, Brenchley PE, et al. Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. Cancer Res 2003;63:812-16.
87. Nian M, Lee P, Khaper N, et al. Inflammatory cytokines and postmyocardial infarction remodeling. Circ Res 2004;94:1543-53.
88. Seta Y, Shan K, Bozkurt B, et al. Basic mechanisms in heart failure: the cytokine hypothesis. J Cardiol Failure 1996;2:243-9.
89. D'Alfonso S, Richardi PM. A polymorphic variation in a putative regulation box of the TNF alpha promoter region. Immunogenetics 1994;38:150-4.
90. Wilson AG, Symons JA, McDowell TL, et al. Effects of a tumor necrosis factor (TNFa) promoter base transition on transcriptional activity. Br J Rheumatol 1994;33(suppl 1):89.
91. Messer G, Spengler U, Jung MC, et al. Polymorphic structure of the tumor necrosis factor (TNF) locus: an NcoI polymorphism in the first intron of the human TNF-b gene correlates with a variant amino acid in position 26 and a reduced level of TNF-b production. J Exp Med 1991;173:209-19.
92. Deten A, Holzl A, Leicht M, et al. Changes in extracellular matrix and in transforming growth factor beta isoforms after coronary artery ligation in rats. J Mol Cell Cardiol 2001;33:1191-207.
93. Song H, Foster AH, Conte JV, et al. Presentation and localization of transforming growth factor beta isoforms and its receptor subtypes in human myocardium in the absence and presence of heart failure. Circulation 1997;197:S362.
94. Awadl-Gamel A, Hasleton P, Turner DM, et al. Genotypic variation in the transforming growth factor-beta 1 gene: association with transforming growth factor-beta 1 production, fibrotic lung disease, and graft fibrosis after lung transplantation. Transplantation 1998;66:1014-20.
95. 1 and tumour necrosis factor-α. Transpl Immunol 1998;6:193-7.
96. Aukrust P, Gullestad L, Ueland T, et al. Inflammatory and anti-inflammatory cytokines in chronic heart failure: potential therapeutic implications. Ann Med 2005;37:74-85.
97. Rosenwasser LJ, Klemm DJ, Dresback JK, et al. Promoter polymorphisms in the chromosome 5 gene cluster in asthma and atopy. Clin Exp Allergy 1995;25(25 suppl 2):74-8.
98. Hobbs K, Negri J, Klinnert M, et al. Interleukin-10 and transforming growth factor-b promoter polymorphisms in allergies and asthma. Am J Respir Crit Care Med 1998;158:1958-62.
99. Kube D, Platzer C, von Knethen A, et al. Isolation of the human IL-10 promoter. Characterization of promoter activity in Burkitt's lymphoma cell lines. Cytokine 1995;7:1-7.
100. Liao W. Endotoxin: possible roles in initiation and development of atherosclerosis. J Lab Clin Med 1996;128:452-60.
101. LeVan TD, Bloom JW, Bailey TJ, et al. A common single nucleotide polymorphism in the CD14 promoter decreases the affinity of Sp protein binding and enhances transcriptional activity. J Immunol 2001;167:5838-44.
102. Morisaki T, Sabina RL, Holmes EW. Adenylate deaminase: a multigene family in humans and rats. J Biol Chem 1990;265:11482-6.
103. Morisaki T, Gross M, Morisaki H, et al. Molecular basis of AMP deaminase deficiency in skeletal muscle. Proc Natl Acad Sci U S A 1992;89:6457-61.
104. Villarreal F, Zimmermann S, Makhsudova L, et al. Modulation of cardiac remodeling by adenosine: in vitro and in vivo effects. Mol Cell Biochem 2003;251:17-26.
105. Frasure-Smith N, Lesperance L, Juneau M, et al. Gender, depression, and one-year prognosis after myocardial infarction. Psychosom Med 1999;61:26-37.
106. Lesch KP, Bengel D, Heils A, et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 1996;274:1527-31.
107. Donahue MP, Allen AS. Genetic association studies in cardiology. Am Heart J 2005;149:964-70.
108. Arab S, Liu PP. Heart failure in the post-genomics era: gene-environment interactions. Curr Opin Mol Ther 2005;7:577-82.
109. Khoury MJ, Little J, Burke W. Human genome epidemiology: a scientific foundation for using genetic information to improve health and prevent disease. New York, NY: Oxford University Press, 2004.
110. Pratt JH, Ambrosius WT, Tewksbury DA, et al. Serum angiotensinogen concentration in relation to gonadal hormones, body size, and genotype in growing young people. Hypertension 1998;32:875-9.
111. Francis SC, Raizada MK, Mangi AA, et al. Genetic targeting for cardiovascular therapeutics: are we near the summit or just beginning the climb? Physiol Genomics 2001;7:79-94.
112. McCarthy JJ, Parker A, Salem R, et al. Large scale association analysis for identification of genes underlying premature coronary heart disease: cumulative perspective from analysis of 111 candidate genes. J Med Genet 2004;41:334-41.
113. Thomas DC, Witte JS. Point: population stratification: a problem for case-control studies of candidate-gene associations? Cancer Epidemiol Biomarkers Prev 2002;11:505-12.
114. Pritchard JK, Rosenberg NA. Use of unlinked genetic markers to detect population stratification in association studies. Am J Hum Genet 1999;65:220-8.
115. Sharp L, Little J. Polymorphisms in genes involved in folate metabolism and colorectal neoplasia: A HuGE review. Am J Epidemiol 2004;159:423-43.
116. Owan TE, Redfield MM. Epidemiology of diastolic heart failure. Prog Cardiovasc Dis 2005;47:320-32.
117. Bax JJ, Poldermans D, Elhendy A, et al. Improvement of left ventricular ejection fraction, heart failure symptoms and prognosis after revascularization in patients with chronic coronary artery disease and viable myocardium detected by dobutamine stress echocardiography. J Am Coll Cardiol 1999;34:163-9.
118. Zintzaras E. Methylenetetrahydrofolate reductase gene and susceptibility to breast cancer: a meta-analysis. Clin Genet 2006;69:327-36.
119. Weir BS. Genetic data analysis II: methods for discrete population genetic data. Sunderland, MA: Sinauer Associates, 1996.
120. Salanti G, Sanderson S, Higgins JP. Obstacles and opportunities in meta-analysis of genetic association studies. Genet Med 2005;7:13-20.
121. Xu J, Turner A, Little J, et al. Positive results in association studies are associated with departure from Hardy-Weinberg equilibrium: hint for genotyping error? Hum Genet 2002;111:573-4.
122. Donahue MP, Marchuk DA, Rockman HA. Redefining heart failure: the utility of genomics. J Am Coll Cardiol 2006;48:1289-98.
123. Kittleson MM, Ye SQ, Irizarry RA, et al. Identification of a gene expression profile that differentiates between ischemic and nonischemic cardiomyopathy. Circulation 2004;110:3444-51.
124. Hauser MA, Li YJ, Takeuchi S, et al. Genomic convergence: identifying candidate genes for Parkinson's disease by combining serial analysis of gene expression and genetic linkage. Hum Mol Genet 2003;12:671-7.
125. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). Circulation 2001;104:2996-3007.
126. Cooper RS. Gene-environment interactions and the etiology of common complex disease. Ann Intern Med 2003;139:437-40.
127. Cordell HJ. Epistasis: what it means, what it doesn't mean, and statistical methods to detect it in humans. Hum Mol Genet 2002;11:2463-8.
128. Zintzaras E, Kitsios G, Stefanidis I. Response to endothelial nitric oxide synthase polymorphisms and susceptibility to hypertension: genotype versus haplotype analysis. Hypertension. Advance Access: November 6, 2006. (DOI: 10.1161/01.HYP.0000251076.18254.ed).
129. Zintzaras E, Kitsios G, Harrison GA, et al. Heterogeneity-based genome search meta-analysis for preeclampsia. Hum Genet 2006;120:360-70.
130. Clayton D, McKeigue PM. Epidemiological methods for studying genes and environmental factors in complex diseases. Lancet 2001;358:1356-60.